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Abstract: There is an increasing awareness of the importance of a diet rich in fruits and vegetables
for human health. Cancer stem cells (CSCs) are characterized as a subpopulation of cancer cells
with aberrant regulation of self-renewal, proliferation or apoptosis leading to cancer progression,
invasiveness, metastasis formation, and therapy resistance. Anticancer effects of phytochemicals are
also directed to target CSCs. Here we provide a comprehensive review of dietary phytochemicals
targeting CSCs. Moreover, we evaluate and summarize studies dealing with effects of dietary
phytochemicals on CSCs of various malignancies in preclinical and clinical research. Dietary
phytochemicals have a significant impact on CSCs which may be applied in cancer prevention
and treatment. However, anticancer effects of plant derived compounds have not yet been fully
investigated in clinical research.
Keywords: cancer stem cells; phytochemicals; plant-derived foods; fruit; vegetable; cell signaling
1. Introduction
Despite progress in anticancer therapy, cancer is a major health problem and one of the leading
causes of morbidity worldwide [1,2]. Cancer is characterized by uncontrolled cell growth, invasiveness,
and formation of metastasis. Malignant tumours are represented by heterogeneous populations of
cancer cells. The heterogeneity may be explained by evolutional accumulation of mutations in one or
few cells or by presence of cells with stem-like properties. Cancer stem cells (CSCs) are characterized
as a subpopulation of cells with an intrinsic ability of self-renewal and differentiation [3–6]. Dietary
phytochemicals are suggested to possess anti-cancer properties with minimal or no side effects [7–9];
moreover, they may also improve the efficacy of chemo- or radiotherapy, and therefore may represent
an important strategy to target CSCs [10].
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1.1. Aim of the Study
The review focuses on the anticancer effectiveness of dietary phytochemicals, either isolated or as
mixtures via targeting CSCs. Firstly, it discusses the basics of CSCs and signaling pathways modulating
their stem-like properties. The core of the review is the summary of preclinical and clinical studies
evaluating whether dietary phytochemicals target CSCs in various malignancies. Plant-derived dietary
compounds which are effective agents against CSCs in preclinical in vitro and in vivo research should
be further evaluated in clinical research. We emphasize the need to include dietary phytochemicals in
the current clinical research.
1.2. Source of Data
Data were recovered from the biomedical literature published in the English-language literature
by use of “cancer stem cells” and “plant-based functional foods“ or “phytochemicals” or “fruit“ or
“vegetables” or “herbs” as either a keyword or medical subject heading (MeSH) term in searches of
the PubMed bibliographic database. We emphasize the most recent scientific papers from the years
2013–2019. About 40 studies were selected with the database accessed between December 2018 and
February 2019.
2. CSCs (Cancer Stem Cells)
CSCs are multipotent cells exhibiting stem-like properties and possessing the capability of the
initiation of tumor growth, invasiveness, and dissemination to distant organs [6,11]. CSCs are like
normal stem cells in several ways; however, if the balance of the influence of internal or external
factors is not maintained, it may lead to hyperproliferation and metastasis [12]. Moreover, CSCs are
resistant to chemical and electromagnetic insults due to their infrequent replication, active drug efflux
system, increase in defense against reactive oxygen species and importantly higher ability of DNA
repairs which may result in a lower rate of apoptosis [13]. Moreover, autophagy is characterized as a
process allowing cells to survive under stress conditions. Accordingly, therapy-resistance and survival
of CSCs may be also associated with increase in autophagy activity [14]. CSCs are also characterized
by active telomerase expression, increased membrane transport activity [2] and hypoxic niche [12].
The survival of stem cells and CSCs depends on their niche or microenvironment which provides
signals regulating their proliferative and self-renewal maintenance [15]. In conclusion, CSCs are
related to the development of cancer, metastasis and resistance to conventional anticancer therapies
and recurrence or relapse of malignancy. Targeting CSCs is a promising strategy of anti-cancer
research [12,16].
2.1. Cancer Stem Cells Markers
CSCs have been recognized in various types of tumors and it is now possible to identify and
isolate them using a distinctive profile of surface (e.g. CD24, CD44, CD133, CD49, CXCR4, LGR5) or
intracellular markers (e.g. ALDH) [17]. Table 1 lists a brief overview of generally accepted markers
associated with CSCs. However, no universal marker for CSCs has been identified [13]. Moreover, their
phenotypes exhibit different markers due to the occurrence of epigenetic alterations, possible presence
of multiple CSCs pools or technical variations [18]. Importantly, these markers are also present in
normal stem cells and other cell types [19]; therefore, a combination of markers is usually required
to denote the CSCs population [20]. CSCs markers are also associated with induction of stem-like
phenotype of cancer cells via modulation of various molecular pathways (Figure 1). On the contrary,
a novel 3D spheroid-based label-retention assay followed by FACS sorting allows the identification
and isolation of stem cells at a single cell level which is considered to be a marker-free method of
isolation of both normal stem cells and CSCs. Consequently, this method dealing with isolation and
characterization of the novel properties of CSCs may be of a great interest in anti-cancer therapeutic
strategy [14]. Moreover, the isolation of stem cells can be also helpful in the understanding of the
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initiation of carcinogenesis as a result of environmental carcinogens targeting stem cells as was
demonstrated by Hu et al. [21] and Prins et al. [22] in in vivo models using prostasphere cells.
Table 1. Markers of CSCs in various tissues.
Cancer type Marker References
Brain cancer CD34+/CD38−/CD133+/CD44+ [6,23]
Breast cancer CD44+/CD24−/Lineage-/ALDH1+/ EpCAM+ [18,20,23]
Colon cancer CD133+/CD44+/CD166+/ ALDH1+/LGR5+/EpCAM+ [6,18,19]
Leukemia CD34+/CD38−/CD90− [6,18,19]
Liver CD133+/CD90+/EpCAM+ [6]
Lung CD133+/CD44+/CD90+ [2,18]
Ovary CD44+/ALDH1+/CD133+ [6,18]
Pancreas CD44+/CD24+/CD133+/EpCAM+ [18,23]
Explanatory notes: + presence; − absence. Abbreviations used: ALDH1-Aldehyde dehydrogenase 1; CD24/34/38/
44/90/133/166-Cluster of Differentiation 24/34/38/44/90/133/166; EpCAM-Epithelial Cell Adhesion Molecule.
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Protein kinase C (PKC) which then phosphorylates transcription factor Nanog resulting in 
upregulation of ATP binding cassette subfamily B member 1 (ABCB1) contributing to multidrug 
resistance (MDR)). CD44 serves as a coreceptor for growth factors and stimulate CSCs self-renewal. 
Tumour necrosis factor alfa (TNF-α) upregulates CD44 through Janus kinase (JNK), thus inducing 
migration, invasion, metastasis or EMT. Cluster of differentiation 24 (CD24) stimulates metastasis 
formation via interaction with P-selectin and cancer progression and trigger EMT via activation of 
Notch1signaling. Cluster of differentiation 133 (CD133) is involved in tumour cell proliferation, 
metastasis, tumorigenesis or therapy resistance – via activation of the phosphatidylinositol-3-kinase 
(PI3K)/Akt. Hypoxia (H) in stem cells and the tumour microenvironment promote CD133 expansion 
via upregulation of hypoxia-inducible factor 1-alpha (HIF-1α). Overexpression of CD133 is associated 
with tumour progression through epidermal growth factor receptor (EGFR)-dependent Akt 
activation. The role of cluster of differentiation 90 (CD90) in cancer depends on the cancer type and 
signaling mechanism. For example, cancer stem-like activity is elevated through up-activation of 
Notch pathway. Increased expression of cluster of differentiation13 (CD13) reduces reactive oxygen 
species (ROS) promoting CSCs survival via EMT. Leucine-rich repeat-containing G-protein-coupled 
5 (LGR5) promotes proliferation of cancer cells via activation of Wnt/β-catenin pathway. Epithelial 
cell adhesion molecule (EpCAM) cleavages with its intracellular domain (EpICD) and provide key 
signals for achieving CSCs properties by modulation of Wnt pathway or LIF/STAT3. Activity of 
Figure 1. Association between surface markers and prom ti n f CS s stem-like properties [3,20,23–41].
Cluster of differentiation 44 (CD44) promotes increase in growth factor beta (TGF-β) leading
to Epithelial–mesenchym l transition (EMT). Binding of hyaluronic acid (HA) with CD44 activates
Protein kinase C (PKC) which then phosphorylates transcription factor Nanog resulting in upregulation
of ATP binding cassette subfamily B m mber 1 (ABCB1) contributing t multid ug resistance (MDR)).
CD44 serves as a coreceptor for growth factors and stimulate CSCs self-renewal. Tumour necrosis
factor lfa (TNF-α) upregulates CD44 through Janus kinase (JNK), thus inducing migration, invasion,
metastasis or EMT. Cluster of differentiation 24 (CD24) stimulates metastasis formation via interactio
with P-selectin nd cancer progression and trigger EMT via activation of Notch1sign ling. Cluster
of differe tiatio 133 (CD133) is involved in tumour cell prolifer tion, metastasis, tumorigenesis
or therapy resistance—via activatio of the phosphatidyl nosit -3-kinase (PI3K)/Akt. Hypoxia
(H) in stem cells and the tumou mic oenvironment promote CD133 expansion via upregulation
of hypoxia-inducible factor 1-alpha (HIF-1α). Overexpression of CD133 is associated with tumour
progression thr ugh epidermal growth f ct r receptor (EGFR -dependent Akt activation. The role of
cluster of differentiation 90 (CD90) in cancer depends on the ance ty e and signaling mechanism.
For ex mple, cancer stem-lik activ ty is elevated through up-activation of Notch pathway. Increased
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expression of cluster of differentiation13 (CD13) reduces reactive oxygen species (ROS) promoting CSCs
survival via EMT. Leucine-rich repeat-containing G-protein-coupled 5 (LGR5) promotes proliferation
of cancer cells via activation of Wnt/β-catenin pathway. Epithelial cell adhesion molecule (EpCAM)
cleavages with its intracellular domain (EpICD) and provide key signals for achieving CSCs properties
by modulation of Wnt pathway or LIF/STAT3. Activity of aldehyde dehydrogenase (ALDH) may
protect CSCs against cell death caused by ROS. ALDHs metabolizes retinoic acid (RA) thus regulating
stem-like properties of CSCs. Aberrantly regulated signaling pathways and cross-talks between them
may ultimately influence their target genes such as c-Myc, cyclinD1, Survivin, Nanog, Oct-4, Sox2, etc.
2.2. EMT (Epithelial–Mesenchymal Transition)
EMT is the reversible change occurring usually during embryogenesis in which epithelial cells
acquire mesenchymal phenotypes [42]; moreover, EMT is an important process during wound healing
and reestablishment of basal and apical polarity [20]. However, EMT is a crucial step in the initiation
of tumor metastasis in which cancer cells alter their morphology, loose epithelial cell-cell junctions
and obtain migratory properties and metastatic capacity. CSCs are considered to possess enhanced
EMT ability, and thus produce metastatic tumors or circulate in the body in a dormant state, until its
activation which may occurs years later [2,20]. EMT also supports the resistance of CSCs to therapeutic
drugs [6]. The process of EMT is associated with modulation of E-cadherin, N-cadherin, vimentin,
C-X-C chemokine receptor type 4 (CXCR4) or cyclooxygenase-2 (COX-2) and also with activation of
transcription factors Snail or Twist [20,43]. It is indicated that metastatic cancer cells undergoing EMT
may possess a CSCs phenotype [44].
2.3. Molecular or Cellular Signaling of CSCs
Strictly regulated signaling pathways control the activity of stem cells [6]. However, some
pathways could be abnormally repressed or activated in human malignancies and these irregularities
contribute to the proliferative, differentiation, self-renewal, and survival properties of CSCs via
aberrant regulation of target genes, such as c-Myc, cyclin D1, Survivin, Nanog, Oct-4, Sox2 and others.
Interestingly, signaling pathways are not linear which means that cross-talk between various pathways
occasionally occur and may lead to consequences including promotion of resistance to therapy, CSCs
expansion or other fatal consequences [40,41].
2.3.1. Signaling Pathways in CSCs
The evolutionary conserved Notch signaling pathway possesses an important role in the balance
of differentiation, cell cycle progression [6], survival, and apoptosis of stem cells. Alterations in this
ligand-receptor pathway guide undifferentiated cells toward malignant transformation and acquisition
of EMT via increased expression of Notch1, Sox2, Nanog, Oct4 or Lin28; moreover the cross-talks
between Notch and other oncogenic signaling pathways also play a crucial role in the development of
cancer [41,45]. Notch signaling is considered to be one of the most activated pathways in cancer cells
and is an important linkage between angiogenesis and CSCs self-renewal [46].
Wnt signaling pathway is involved in embryonic development and homeostasis of tissues.
Evolutionary conserved and highly complex Wnt signaling is considered to encompass two pathways
which are not exclusive and cross-talk may occur between them. β-catenin-independent pathway (or
noncanonical) with calcium as the major mediator regulates asymmetrical division of cells, cell polarity
and migration [40,45]. On the contrary, the transcriptional regulator β-catenin-dependent (canonical)
pathway regulates the survival and proliferation of cells [47]. The aberrant activation of Wnt pathway
and deregulated expression of Wnt-binding proteins, ligands, inhibitors or other co-regulators is
associated with various human malignancies, acquisition of EMT phenotype, self-renewal or cancer
cell dedifferentiation into CSCs. Targeting Wnt may be another option of decreasing or eliminating
CSCs [41,45].
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The Hedgehog (HH) signaling pathway plays a crucial role in the embryonic development,
especially the development of skin, hair follicles and sebaceous glands and also in adult brain
development [6]. Moreover, HH functions in the regulation of proliferation, maintenance of the stem
cells and progenitor cell and self-renewal capacity [48]. There are several Hedgehog homologues which
are well studied in mammals including sonic (sHH), desert (dHH), and indian (iHH). Significantly,
it is supposed that HH plays an important role in the process of acquiring stem cell-like properties
during the EMT [41]. For instance, aberrant activation of sHH/transcription factor GLI1 signaling may
lead to changes in expression of GLI1-regulated oncoproteins like N-myc, CyclinD1, Foxm1, and Bcl-2
playing a crucial role in CSCs self-renewal [49].
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR)
is a signaling pathway playing crucial role in metabolism, proliferation, angiogenesis, differentiation,
and survival of cells [48]. It is abnormally regulated in cancer cells due to mutation, deletion,
methylation, amplification or post-translational modifications and is important for regulation of
apoptosis, radioresistance, metastasis, and maintenance of CSCs populations. Phosphatase and tensin
homolog (PTEN) is suggested to be a negative regulator of PI3K/Akt/mTOR pathway and also to
function as a tumour suppressor [50]. Components of PI3K pathway are considered to be the most
activated and mutated in human cancers, thus it is important to consider its targeting in cancer
treatment [51].
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signaling
pathway possess and important role in cytokines and growth factor signaling affecting cell growth,
proliferation and immune response. Aberrant regulation of the JAK/STAT pathway is associated
and implied with maintenance of germ-line stem cell populations in various cancers [48]. Moreover,
interleukin-8 (IL-8) is suggested to trigger the activation of STAT3 which may lead to inflammation,
ROS production and multidrug resistance (MDR) [52]. More detailed overview of aberrantly regulated
CSCs signaling pathways attributed to various malignancies is shown in Table 2. Importantly, this
table is adjusted to several concrete cancer types, and thus other abnormally regulated pathways or
signaling molecules, which are not mentioned, may be also responsible for the CSCs-phenotype of
other malignancies.
Table 2. Cancer stem cells signaling pathways aberrantly regulated in selected malignancies.
Signaling Pathway Cancer type Mechanism of action References
Notch
Brain cancer ↑Notch1 ↑JAG1 ↑DLL1
[6,40,44]
T cell acute lymphoblastic
leukemia ↑ Notch1
Breast cancer ↑Notch1 ↑JAG1,
Pancreatic cancer ↑Notch1 ↑Notch3↑Jag1 ↑Jag2 ↑Hes1
Non-Small Lung Cancer ↑ Notch3
Wnt/β-catenin
Breast cancer
↑LEF-1 ↑TCF-4
↑cyclin D1 ↑β-catenin
↓SFRP
[6,40,41,47]Colorectal carcinoma
Brain tumor
Prostate cancer
Mutations in APC/β-catenin
site
Hematologic cancer
Skin cancer
Lung cancer
↓WIF-1 ↓SFRP-1
↓ DKK ↓AXIN2
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Table 2. Cont.
Signaling Pathway Cancer type Mechanism of action References
Hedgehog
Colon cancer ↑sHH ↑GLI2
[6,40]
Medulloblastoma
predisposition Mutations in PTCH1
Myeloma ↑SMO ↑GLI1
Glioma ↑GLI1 ↑SHH↑PTCH1
PI3K/Akt/mTOR
Gastric cancer ↑Akt1
[19]
Ovarian cancer
Pancreatic cancer ↑Akt2
T cell acute lymphoblastic
leukemia
Melanoma
Endometrial carcinoma
Prostate cancer
Glioblastoma
Mutations in PTEN
JAK/STAT
Breast cancer
Gastric cancer
Glioblastoma
↑STAT3 [40,53,54]
Explanatory notes: ↓decrease; ↑increase.
Abberant regulation of Notch signaling may be modulated via abnormal expression of Notch
ligands including Delta-like (DLL1/3/4) and JAGGED (JAG1/2), Notch receptors (Notch1–4) or
Notch target genes (Hes1). Wnt/β-catenin pathway may contribute to cancer-like phenotype of
cells via abnormal expression of Secreted frizzled-related proteins (SRFP-1), Wnt inhibitory factor
(WIF), Dickkopf-related protein (DKK), Axis inhibition protein 2 (AXIN2) and increased levels of Wnt
signaling proteins including Lymphoid enhancer-binding factor 1 (LEF-1) or T-cell factor 4 (TCF-4)
binding to which β-catenin influence expression of target genes (eg. Cyclin D or c-Myc). Deregulation
of Hedgehog (HH) pathway may be influenced via aberrant expression of HH ligands (sonic, desert,
indian), receptors PATCHED (PTCH), transmembrane proteins SMOOTHENED (SMO) or transcription
factors Zinc finger proteins (GLI1-3). Abnormal modulation of PI3K/Akt/mTOR may be based on
dysregulated Protein kinase B (Akt) or negative regulator of the Phosphatase and tensin homolog
(PTEN). JAK/STAT signaling may be deregulated via abnormal expression of Signal transducer and
activator of transcription 3 (STAT3).
2.3.2. Apoptotic and Death Resistance Signaling of CSCs
Apoptosis is regulated by an extrinsic or intrinsic pathway. Dysregulated apoptosis is a hallmark
of cancer, and failure in signaling either of extrinsic or intrinsic pathways occurs also in CSCs [2,55].
Deficiency in apoptotic pathways of CSCs is induced via various mechanisms. Firstly, upregulation of
cFLIPs, FLICE-like inhibitory proteins functioning as negative modulators of death receptor-induced
apoptosis, and dysregulated expression of Bcl-2 family members are critical for the survival of CSCs.
Additionally, increase in expression of inhibitors of apoptosis proteins (IAPs) is also associated with
the tendency of CSCs to evade apoptosis. An increase in survivin, antiapoptotic protein which belongs
to IAP family, may also contribute to maintenance of CSCs [55,56]. Furthermore, it is suggested that
chemo- or radioresistance of CSCs is dependent on interleukin-4 (IL-4) signaling pathway because
upregulation of the already mentioned pathway may result in apoptosis resistance [6]. Increase in
autophagy flux is also observed in stem cells; therefore it may be related with therapy resistance
of CSCs (Hu et al. [14]). Cancer cells may contain activated nuclear factor-κB (NF-κB) and tumour
necrosis factor receptor-1 associated death domain protein (TRADD) which is considered to possess
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an important role in NF-κB activation and survival of CSCs [56]. NF-κB enables CSCs to mediate
metastasis [40] and cooperates with other pathways which are associated with CSCs, such as Notch,
TGF-β or STAT3 [57]. Importantly, activation of nuclear respiratory factor 2 (Nrf-2) may lead to
inhibition of NF-κB signaling [58]. In addition, overactivation of ATP-binding (ABC) efflux multidrug
resistance transporters, which induce resistance to chemotherapy, was observed to be highly expressed
in various CSCs. Moreover, hypoxia-inducible factor 1 (HIF-1) mediating efflux of chemotherapy
is implicated in resistance of CSCs to chemotherapy. The use of agents reducing efflux may be a
viable strategy targeting CSCs. Activation of enzyme aldehyde dehydrogenase (ALDH) is associated
with drug metabolic activities. Restoration of apoptotic processes in CSCs may lead to increased
sensitiveness of CSCs to anticancer strategies [56,59].
In conclusion, multiple mechanisms are involved in regulation of the stem-cells related processes
of self-renewal, differentiation or apoptosis, many of them are deregulated in CSCs. Figure 2 depicts
an overview of signaling pathways involved in the maintenance of CSCs survival, self-renewal,
differentiation, and mechanisms of death resistance. Nevertheless, several pharmaceuticals and dietary
phytochemicals were suggested to repair these abnormally regulated cellular or molecular signaling
pathways in CSCs, and thus function as anticancer agents. In the following chapter we will focus on
anticancer effects of dietary phytochemicals (isolated and/or compounds) in CSCs.
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Figure 2. Mechanisms involved in stem-like maintenance and death resistance of CSCs.
Self-renewal, differentiation and maintenance of other stem-like properties may be mediated via
modulation of signaling pathways including Notch, Wnt/β-catenin, Hedgehog, PI3K/Akt, JAK/STAT
and others. cFLIPS, FLICE-like inhibitory proteins; IAPs, inhibitors of apoptosis proteins; Bcl-2, Bcl-2
family proteins; ABC, ATP-binding efflux multidrug resistance transporters; HIF-1, hypoxia-inducible
factor 1; IL-4, interleukin-4; NF-κB, nuclear factor-κB are suggested to modulate CSCs resistance to
death and cancer therapies.
3. Natural Compounds T rg ting CSCs in Cancer Research
The importance of natural compounds in cancer treatment or prevention is supported by abundant
evidence from cancer research [60]. Natural products are a source of bioactive compounds [20]
demonstrating antioxidant, proapoptotic, and antiproliferative effects on a variety of cancers, for which
existence of CSCs have been reported [61]. Significantly, dietary phytochemicals possess an ability of
multilateral targeting of cellular and molecular signaling pathways which are abnormally activated
in CSCs [18,59]. Since the first identification of CSCs in the late 1990s, there is great interest of this
approach in cancer research [15]. Although, the clear evidence of phytochemicals targeting CSCs was
in the early 21st lacking, a possible association between phytochemicals and their potential anti-CSCs
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effects was indicated by several studies. Jaiswal et al. [62] and Ryu et al. [63] suggested an active role
of curcumin in the Wnt/β-catenin attenuation in colon cancer cells. Moreover, downregulation of
Notch1 was observed in pancreatic cancer cells [64]. However, more recent evidence from various
preclinical and clinical studies suggests a direct association of natural bioactive compounds either in
form of isolated dietary phytochemicals or in a form of plant functional foods in targeting CSCs.
3.1. Preclinical Research
3.1.1. Isolated Phytochemicals
Epigallocatechin-3-gallate (EGCG) is the main constituents of green tea and its protective effects
are associated with various human malignancies whereas the combination of EGCG and anticancer
therapy is more effective for inhibiting CSCs [65]. Interestingly, EGCG diminished lung CSCs
activity in vitro via inhibition of tumorsphere formation, decrease in CSCs markers, suppression
of proliferation, and induction of apoptosis. The mechanism of already mentioned effects of EGCG is
attributed to the modulation of the Wnt/β-catenin pathway [66]. EGCG also inhibited self-renewal
capacity of head and neck CSCs by attenuating the expression of stem cell markers and suppressing
sphere forming capacity. Moreover, EGCG augmented cisplatin-mediated chemosensitivity by
suppression of ABC transporter genes, inhibited tumor formation and induced apoptosis in xenograft
model. The presumed mechanism of the anti-CSCs activity of EGCG is attributed to decrease in
transcription level of Notch signaling components [67].
Resveratrol is a protective ingredient widely spread in the traditional Mediterranean diet which
is considered to lower the risk of cancer. Resveratrol and its analogue pterostilbene target CSCs via
multiple signaling pathways [68]. Resveratrol is characterized as polyphenolic stilbene derivate found
in the skin of grapes and berries which possess antioxidant, anti-inflammatory, and anticarcinogenic
properties [20]. Resveratrol suppressed the Wnt/β-catenin signaling pathway in breast CSCs in vitro
and in vivo, and thus inhibited breast cancer stem cells and induced autophagy [69]. Moreover,
resveratrol was found to impair glioma stem cells proliferation and motility by modulating the
Wnt signaling and EMT activators in glioblastoma multiforme lines [70]. Furthermore, resveratrol
eliminated CSCs of osteosarcoma by reduction of expression of cytokines activating JAK/STAT
signaling [71]. Pterostilbene is a bioactive compound of blueberries and grapes gaining an attention
due to its chemo-preventive effects in a variety of cancer types. Tumor-associated macrophages (TAM)
are suggested to promote metastasis and malignancy; interestingly, it is suggested that pterostilbene
influences CSCs/TAM regulation in breast cancer. Pterostilbene suppressed the generation of breast
CSCs via modulation of NF-κB/microRNA 448 circuit [72]. Moreover, pterostilbene was found
to function as an anticancer stem cell agent via suppressing irradiation-mediated enrichment of
CD133+ Mahlavu cells, preventing tumor sphere formation, reducing stemness gene expression and
suppressing invasion, migration, and process of EMT in hepatoma CSCs [43].
Genistein is a soy isoflavone functioning as a natural NF-κB inhibitor [73]. Genistein is
associated with antitumor effects in various malignancies, especially in breast and prostate cancer.
The study evaluating effects of genistein in vitro and in vivo was performed in MCF-7 breast cancer
cells and in nude mice. Genistein inhibited breast cancer stem cells through down regulation of
Hedgehog-GLI1 signaling pathway [74]. Moreover, genistein was found to inhibit stemness of SKOV3
cells induced by macrophages co-cultured with ovarian cancer stem-like cells thus becoming a
potential chemo-preventive agent in human ovarian cancer. Genistein disrupted interaction between
OCSLCs and THP-1 macrophages via blocking IL-8/STAT3, reversing M2 polarization of macrophages
and inhibiting stemness of SKOV3 cells in co-culture system and co-injection in nude mice [52].
7-Difluoromethoxyl-5,4′-di-n-octyl genistein (DFOG) is a novel synthetic genistein analogue. DFOG
inhibited stem-like properties and reverse EMT phenotype in gastric cancer stem-like cells in vitro [75].
Curcumin is a dietary polyphenol derived from Curcuma longa. Curcumin targets CSCs through
acting on the signaling pathways including Wnt, HH or Notch [76,77]. Importantly, curcumin decreased
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CSCs markers in Burkitt lymphoma and acute myeloid leukemia cell line via modulation of self-renewal
CSCs mechanisms [78]. Another study evaluated effects of curcumin on the reduction of breast CSCs
population for sensitizing cancer cells to mitomycin C. Curcumin sensitized breast cancer cells to
chemotherapy via decrease in ABC transporter (ABCG2) expression [79]. Curcumin also suppressed
malignant glioma cells growth and induced apoptosis via inhibition of sHH/Gli1 pathway in vitro
and in vivo [49]. Curcumin also induced cell cycle arrest via regulation of G0/G1 phase related factors
including cyclin D1, cyclin-dependent kinase 2 (CDK-2), nuclear factor erythroid 2–related factor 2
(p21) and cyclin-dependent kinase inhibitor 1 (p27) and apoptosis in prostate cancer cells in vitro via
down regulation of Notch signaling [80].
Isothiocyanates (ITCs) suppress cellular proliferation, EMT and self-renewal of CSCs via inhibition
of oncogenic signaling pathways such as NF-κB, STAT3 or other pathways which are found to be
upregulated in various cancers [81]. Phenethyl isothiocyanate (PEITC) and sulforaphane are most
widely investigated isothiocynates of cruciferous plants [82]. Sulforaphane reduced tumor growth
of orthotopically implanted primary pancreatic CSCs into NOD/SCID/IL2Rgamma mice, isolated
from human pancreatic tumors via modulation of Sonic hedgehog-GLI pathway. Despite reduced
expression of sHH components, sulforaphane also inhibited pluripotency maintaining transcription
factors and markers of angiogenesis including vascular endothelial growth factor (VEGF) together with
platelet-derived growth factor receptor alpha (PDGFRα). Interestingly, all of them are downstream
targets for GLI transcription. Sulforaphane also reduced markers of EMT, in which Zinc finger
E-box-binding homeobox 1 (Zeb-1) is included [83]. Moreover, sulforaphane inhibited CSCs properties
and enhanced therapeutic efficacy of cisplatin in NSCLC through up-regulation of miR-214 which then
targeted c-Myc in vitro and in xenografted nude mice [84]. Additionally, sulforaphane suppressed
the growth of triple-negative breast cancer stem-like cells in vitro and in vivo via modulation of
stem-related embryonic oncogene CRIPTO-1/TDGF1 (CR1) and its homologue CR3. Despite the
crypto-modulated pathway, sulforaphane decreased expression of various stem cell markers [85].
PEITC is an effective inhibitor of colorectal CSCs by targeting Wnt/β-catenin pathway in vitro. PEITC
reduced the size and number of cell spheroids and expression of CSCs markers and suppressed
colony formation and proliferation indicating the repression of self-renewal ability [77]. PEITC also
suppressed pluripotency factors, self-renewal capacity, and clonogenicity of CSCs in vitro CSCs model
derived from colon cancer cells and in a mouse xenograft model injected with EpCAM-expressing
cells [86].
Diallyl trisulfide (DATS) is a garlic derived organosulfur suggested to possess anticancer
properties. DATS reduced tumorsphere formation, decreased CSCs markers expression, inhibited
proliferation and induced apoptosis via inhibition of Wnt/β-catenin pathway and its target genes in
colorectal cancer cell line [87]. Similarly, DATS inhibited the viability of CSCs, decreased expression of
CSCs markers, inhibited proliferation and induced apoptosis in human breast cancer cell line also via
inhibition of Wnt/ β-catenin pathway [88].
3.1.2. Plant-Derived Functional Foods
Anti-cancer research demonstrated benefits of phytochemicals combinations over isolated
phytochemicals [89]. Plant-derived functional foods contain various bioactive compounds, and
therefore are effective agents targeting CSCs. Several studies evaluated anti-CSCs effectiveness
of plant-functional foods in preclinical research. Green algae Capsosiphon fluvescens glycoprotein
downregulated the Wnt-1 signaling pathway in human gastric cell line, and therefore inhibited gastric
cancer cell migration [90]. Anticarcinogenic effects of plant derived functional foods were evaluated
in the chemopreventive models of experimental rat mammary carcinogenesis. Administration of
Origanum vulgare L. in diet in the lower dose (0.1%) suppressed expression of CD24 by 34% and
by 57% in the higher dose (1%). Moreover, the level of expression of EpCAM was decreased
by 14% and 10% respectively. Furthermore, dietary administration of Syzygium aromaticum L. in
high dose (1%) showed decrease in expression of CD24 and CD44 and increase in expression
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of ALDH1. These effects on CSCs were associated with significant chemopreventive activity in
both studies [91,92]. Pomegranate (Punica granatum L.) is a fruit rich in nutrients and bioactive
phytochemicals [93]. A pomegranate emulsion was found to possess chemopreventive properties
against DMBA-induced mammary tumorigenesis in rats via disruption of Estrogen Receptor and
Wnt/β-catenin signaling pathways [94]. Further investigation revealed that preventive effects of
pomegranate extract in DMBA-evoked mammary carcinogenesis involve anti-inflammatory regulation
of two interrelated pathways NF-κB and Nrf2 [93], and this mechanism may be interrelated with
CSCs signaling. Trianthema portulacastrum L. is an exotic plant exhibiting various pharmacological
properties including antibacterial, antifungal, anti-inflammatory or antioxidant effects. T. portulacastrum
extract (TPE) was found to prevent DMBA-induced breast carcinogenesis by anti-inflammatory
mechanism mediated via modulation of NF-κB and Nrf signaling pathways [94]. Moreover, extract
of Geissospermum vellosii also known as Pao Pereira, inhibited pancreatic CSCs via modulation of
Wnt/β-catenin in vitro and in vivo [95]. Similarly, pancreatic CSCs were inhibited by extract of
traditional African plant Rauwolfia vomitoria in vivo and in vitro also via modulation of Wnt/β-catenin
signaling pathway [96]. Significantly, Chinese bayberry (Myrica rubra) leaf proanthocyanidins (BLPs)
containing epigallocatechin-3-O-gallate (EGCG) as their terminal and major extension units exhibited
inhibitory effects on chemotherapy-resistant OVCAR-3 spheroid cells via modulation of cell viability
and sphere and colony formation. Furthermore, BLPs also inhibited self-renewal abilities of CSCs
via targeting Wnt/β-catenin signaling pathway [97]. The anticancer benefits of three marine brown
seaweed polyphenol extractions including Hormophysa triquerta (HT-EA), Spatoglossum asperum (SA-EA)
or Padina tetrastromatica (PT-EA) were explored utilizing pancreatic cancer (PC) stem cells grown ex
vivo and mouse model of residual-PC. Results of the study demonstrated the ability of these extracts to
target signaling pathways playing critical role in the regulation of EMT, pluripotency and maintenance
of CSCs after first-line therapy [98]. Water extract of Gynura divaricata (GDE) was found to target liver
CSCs in a moderate to weak level and to sensitize Huh7 cell to cisplatin therapy by regulation of
Wnt/β-catenin pathway and target genes [99].
Moreover, the efficacy of resveratrol (RSV) in combination with grape seed extract (GSE)
was investigating in isolated human colon CSCs in vitro and in an azoxymethane-induced
mouse model of colon carcinogenesis in vivo. RSV-GSE suppressed Wnt/β-catenin and induced
mitochondrial-mediated apoptosis of CSCs [100]. A summary evaluating the anti-CSCs mechanisms
of phytochemicals (isolated or mixtures) is shown in Table 3.
Table 3. Anticancer mechanisms of dietary phytochemicals (isolated or mixtures) targeting CSCs.
Phytochemical
(Isolated or Mixture) Cell Line/Animal Model Mechanism References
EGCG A549, H1299
↓β-catenin
↓CD133 ↓CD44
↓ALDH1A1
↓Nanog ↓Oct4
[66]
EGCG/
EGCG and cisplatin
HNSC CSCs
BALB/c nude mice
↓Oct4 ↓Sox2 ↓Nanog
↓CD44
↓ABCC2 ↓ABCG2
[67]
Resveratrol
MCF-7, SUM159
NOD/SCID xenografted
mice
→autophagy
↓Wnt/β-catenin [69]
GBM2, GBM7, G144, G179,
G166, GliNS2, GBM04
↓β-catenin ↓c-Myc
↓Twist1 ↓Snail1 [70]
MNNG/HOS. MG-63,
hFOB1.19
↓JAK2/STAT3
↓CD133 [71]
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Phytochemical
(Isolated or Mixture) Cell Line/Animal Model Mechanism References
Pterostilbene
MCF7, MDA-MB-231
↓NF-κB ↓Twist1
↓vimentin
↑E-cadherin
[72]
HCC Mahlavu
↓c-Myc ↓COX-2
↓vimentin ↓CXCR4
↓Twist1
[43]
Genistein
MCF-7
Nude mice
↓SMO
↓GLI1 [74]
SKOV3
Nude mice
↓CD 163 ↓p-STAT3
↓IL-10 ↑IL-12
↓CD133 ↓CD44
[52]
GCSLCs
↓ Twist1
↓N-cadherin
↑E-cadherin
↓CD133 ↓CD44 ↓ALDH1
[75]
Curcumin
BL41-3, Ramos, DG-75,
THP-1
↓ALDH+ cells ↓GLI1
↓Notch1 ↓cyclin D1 [78]
MCF-7, MDA-MB-231
Athymic mice ↓ABCG2 ↓ABCC1 [79]
U87, T98G
U87-implanted nude mice
↓sHH
↓SMO ↓GLI1
↓cyclin D1
↓Bcl-2 ↓FoxM1
↑Bax/Bcl-2 ratio
[49]
DU-145
↓cyclin D1 ↓CDK2 ↓Bcl-2
↑p21 ↑p27 ↑p53 [80]
Sulforaphane
NOD/SCID/IL2Rgamma
mice
↓SMO ↓GLI1 ↓GLI2
↓Nanog ↓Oct-4 ↑Bcl-2
↓Zeb-1 ↓E-cadherin
↓VEGF ↓PDGFRα
[83]
BalbC/nude mice
↓CR1 ↓CR3
↓Nanog ↓ALDHH1A1
↓Wnt3 ↓Notch4
[85]
BEAS-2B, H460, H1299,
A549 ↓c-Myc [84]
Phenethyl isothiocyanate
DLD-1
SW480
↓size/number of cell
spheroids
↓CD133+
[77]
293T, NCCIT, HCT116
Xenograft model ↓Oct4 ↓Sox-2 ↓Nanog [86]
Diallyl trisulfide
SW48, DLD-1 ↓β-catenin↓c-Myc ↓cyclin D1 [87]
MCF-7, SUM159
↓CD44 ↓ALDH1A1
↓Nanog
↓Oct4
[88]
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Table 3. Cont.
Phytochemical
(Isolated or Mixture) Cell Line/Animal Model Mechanism References
Capsosiphon fulvescens AGS ↓Wnt-1 ↓β-catenin→ G0/G1 arrest [90]
Origanum vulgare NMU-induced ratmammary carcinogenesis
↓CD24
↓EpCAM [91]
Syzygium aromaticum NMU-induced ratmammary carcinogenesis ↓CD24 ↓CD44 ↑ALDH1 [92]
Pomegranate extract DMBA-induced ratmammary carcinogenesis
↓ER-α:ER-β↓β-catenin
↓cyclin D1 ↓COX-2
↑Nrf2
IκBα degradation and
NF-κB translocation
blockage
[93]
Trianthema portulacastrum
extract
DMBA-induced rat
mammary carcinogenesis
↓COX-2 ↑Nrf2
IκBα degradation and
NF-κB translocation
blockage
[94]
Pao Pereira extract
PANC-1, MIA PaCa-2,
AsPC-1, HPAF-II, BxPC-3
in immunocompromised
mice
↓Nanog
↓β-catenin [95]
Rauwolfia vomitoria
extract
PANC-1, AsPC-1, HPAF-II,
BxPC-3 and MiA PaCa-2 in
immunocompromised
mice
↓Nanog
↓β-catenin [96]
Chinese bayberry leaf
proanthocyanidins
(BLPs)
OVCAR-3
↓β-catenin ↓cyclin D1
↓c-Myc
→G1 arrest
[97]
HT-EA, SA-EA, PT-EA
Panc-1, MiaPaCa-2,
Panc-3.27, and BxPC-3
Athymic NCr-nu/nu nude
mice
↓Nanog ↓Oct-4
↓Sox2 ↓N-cadherin [98]
Water extract of Gynura
divaricata (GDE) Huh7, Hep3B ↓β-catenin [99]
Resveratrol (RSV) and
grape seed extracts (GSE)
Human colon CSCs
Azoxymethane-induced
mice
↓ nuclear translocation of
β-catenin
↓c-Myc
↓cyclin D1
↑p53
↑Bax/Bcl-2
[100]
Explanatory notes: ↓ decrease; ↑ increase;→ induction. Abbreviations used: ABCC1-ATP Binding Cassette Subfamily
C Member 1; ABCC2-ATP Binding Cassette Subfamily C Member 2; ABCG2-ATP Binding Cassette Subfamily G
Member 2; ALDH1A1-Aldehyde Dehydrogenase 1 Family Member A1; Bcl-2-B-cell Lymphoma Protein Family
CD136/133/44/24, Cluster of Differentiation 136/133/44/24; CDK2-Cyclin-dependent Kinase 2; c-Myc, MYC
protoonkogene; COX-2-Cyclo- oxygenase 2; CR1-CRIPTO-1/TDGF1, Teratocarcinoma-derived Growth Factor
1, CR3, CRIPTO-3/TDGF1P3, Putative Teratocarcinoma-derived Growth Factor 3; CXCR4-Chemokine Receptor
Type 4; EpCAM-Epithelial Cell Adhesion Molecule; ERα-Estrogen Receptor Alfa; ERβ-Estrogen Receptor Beta;
FoxM1-Forkhead Box Protein M1; GLI1/2-Zinc Finger Protein 1/2; IL-10/12-Interleukin 10/12; JAK-Janus kinase;
NF-κB-Nuclear Factor Kappa-light-chain-enhancer of Activated B cells; Notch1-4-Notch receptors; NRF2-Nuclear
Factor Erythroid 2–related Factor 2; p21-Cyclin-dependent Kinase Inhibitor 1; p27-Cyclin-dependent Kinase Inhibitor
1B; p53-Tumour Protein p53; PDGFRα-Platelet-derived Growth Factor Receptor Alpha; pSTAT3-Phospho-Signal
Transducer and Activator of Transcription 3; sHH- Sonic Hedgehog; SMO- Transmembrane protein SMOOTHENED;
Snail1-Zinc Finger Protein; STAT-Signal Transducer and Activator of Transcription; Twist1-Twist family BHLH
Transcription Factor 1/gene; VEGF-Vascular Endothelial Growth Factor; Zeb-1-Zinc finger E-box-binding
Homeobox 1.
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3.2. Clinical research
Anti-CSCs potential of dietary phytochemicals (isolated or mixtures) was investigated in several
previously mentioned preclinical studies [43,49,52,66,67,69–72,74,75,77–80,83–88,90–100]. Significantly,
anticancer properties of phytochemicals were evaluated in several clinical trials. Firstly, a phase I pilot
study on patients with colon cancer was conducted to evaluate effects of a low dose of resveratrol
formulation and resveratrol-containing freeze-dried grape powder (GP) on Wnt signaling in the colon.
Results of the trial are based on the expression of Wnt target genes. Resveratrol/GP inhibited Wnt
target gene expression in normal colon mucosa; however did not inhibit the Wnt pathway in colon
cancer tissue [101]. Moreover, a phase 2 randomized, placebo-controlled trial was conducted on
59 subjects diagnosed with urothelial bladder cancer. The aim of the trial was to investigate whether
daily dose of genistein in the form of purified soy extract G-2535 for 14 to 21 days before surgery alter
molecular pathways in bladder epithelial tissue. The primary outcome of the study was inhibition
of EGFR phosphorylation in a dose of 300mg/d. However, no significant changes were observed in
expression of COX-2, Ki67, caspase-3, Akt or p-Akt [102]. Furthermore, a randomized clinical trial
on 35 colorectal cancer patients, who were daily administrated 900 mg of ellagitannins-containing
pomegranate extract (PE) showed the expression of CRC-genes in normal and cancerous colon tissue
was evaluated before (biopsies) and after (surgical specimens) 5–35 days of supplementation. Tissues
were also obtained from a control group of patients with no supplementation. The consumption of
the PE was significantly associated with a counterbalance effect in the expression of CD44, β-catenin,
p21 or others suggesting that the intake of PE modulated the impact on gene expression in a gene-
and tissue-specific manner [103]. While searching in the clinical trial database [104], we found few
clinical trials which may be partially related to CSCs. A prospective phase II study was initiated
in 2015 with the aim to investigate the effect of Fursultiamine, a derivate of vitamin B, combined
with concurrent chemo/radiotherapy in esophageal cancer patients (ClinicalTrials.gov Identifier:
NCT02423811). Moreover, pancreatic ductal adenocarcinoma (PDA) stem cells were target of a pilot
study initiated in 2013 with the aim to find whether the application of freeze-dried broccoli sprouts
lead cancer inhibition in patients with advanced PDA (ClinicalTrials.gov Identifier: NCT01879878).
However, no results of these clinical trials are available at this time.
Figure 3 shows an overview of dietary phytochemicals (isolated or mixtures) in preclinical or
clinical research and their effects on CSCs. Finally, there is number of clinical trials evaluating plant
derived foods or dietary supplements in anticancer research; however, we were not successful in
finding clinical trials focusing on CSCs specifically.
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Isolated dietary phytochemicals including diallyl trisulfide, pterostilbene, sulforaphane,
resveratrol, curcumin, genistein, epigallocatechin-3-gallate (EGCG), phenethyl isothiocyanate (PEITC)
and plant functional foods including S. aromaticum, C. fluvescens, O. vulgare, Chinese bayberry leaf
proanthocyanidins (BLPs) and extracts of pomegranate, Trianthema portulacastrum, Gynura divaricata,
Hormophysa triquerta (HT-EA), Spatoglossum asperum (SA-EA), Padina tetrastromatica (PT-EA) and
resveratrol in combination with grape seed extracts (GSE) demonstrated anticancer properties via
targeting CSCs-mediated pathways and thus modulating CSCs proliferation, invasiveness, migration,
self-renewal, EMT and sensitivity to therapeutic approaches in preclinical research. The data evaluating
effects of dietary phytochemicals in clinical research were insufficient. Ellagitannins-containing
pomegranate extract (PE) and purified soy extract (G-2535) may modulate CSCs signaling at least
partially. Resveratrol formulation and resveratrol-containing freeze-dried grape powder RSV/GP
did not exhibit any prosperous effects in inhibition of CSCs pathways in cancer tissue. Clinical trials
evaluating anticancer effects of broccoli sprouts and fursultiamine were initiated in 2013 and 2015,
however no results were reported for these studies.
4. Conclusion and Future Perspectives
There is great evidence suggesting that aberrant regulation of CSCs signaling pathways may lead
to deregulation of self-renewal, apoptosis, proliferation, and importantly resistance to anti-cancer
therapy. Considering the cancer research, phytochemicals (isolated or mixtures) are suggested
to possess antioxidant, antiproliferative, and anticancer properties and also to have the ability to
target aberrantly regulated signaling of CSCs. Importantly, the use of plant derived compounds is
associated with no or very little adverse events. Phytochemicals are thought to modulate various
signaling pathways of CSCs. Cross talk between these pathways influence self-renewal, differentiation,
EMT, therapy resistance and other pro-cancer mechanism associated with stem-like cells. Here
we summarized the current state of the anticancer effectiveness of different plant-derived dietary
phytochemicals in preclinical and clinical research. In vitro and in vivo preclinical studies indicated
significant anticancer effects of dietary phytochemicals mediated by CSCs targeting via modulation of
signaling pathways, including Wnt, Notch, Hedgehog, or other, as well as via regulation of mechanisms
involved in the processes of apoptosis or drug resistance. Based on the comparative preclinical
oncology studies, functional foods (characterized by the presence of mixture of phytochemicals) are
suggested to exhibit better anti-cancer activities (including the anti-CSCs properties) when compared
to isolated phytochemicals. Importantly, each of the preclinical studies included in our review is
specific in its aims and uses specifically designed methods. However, individual processes in the cell
and therefore processes of carcinogenesis are complex and interconnected. Nevertheless, it would be
beneficial to find out if there are associations or discrepancies between studies dealing with the same
type of cancer, cell line, model, phytochemical or specific pathway responsible for anti-CSCs effects of
particular substance. After all, more specific and comparative studies are needed for such analysis.
Despite numerous preclinical studies, clinical research in this area is significantly lagging behind and
only a few trials could be identified. On the contrary, we have encountered a large number of clinical
studies focused on how are CSCs influenced by synthetic drugs; however, evidence of plant-derived
foods or other dietary supplements as anti-CSCs agents is lacking. In conclusion, we emphasize the
significant anti-cancer effects of dietary phytochemicals on CSCs in a wide range of cancer types via
influencing multiple signaling mechanisms, and thus demonstrating the urgent need for their in-depth
investigation in clinical research.
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